BofA lowered the firm’s price target on RxSight (RXST) to $36 from $60 and keeps a Buy rating on the shares. Shares are down 61% since hitting all-time highs in June 2024 as the stock re-rated after inline Q3/Q4 results and a generally tougher macro environment for high growth, not yet profitable medtech companies, the analyst tells investors in a research note. The firm thinks the stock could be rangebound near-term with only an inline Q1.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Path to Profitability: A Buy Rating Amid Revenue Growth and Operational Leverage
- RxSight price target lowered to $28 from $33 at Stifel
- Promising Growth and Competitive Edge: A Buy Rating for RxSight
- RxSight, Inc. Reports Strong Revenue Growth Amid Challenges
- RxSight price target lowered to $44 from $58 at BTIG